No Matches Found
No Matches Found
No Matches Found
Yasons Chemex Care Ltd
Is Yasons Chemex overvalued or undervalued?
As of November 18, 2025, Yasons Chemex is considered overvalued with a PE ratio of 14.81 and an EV to EBITDA ratio of 28.09, especially when compared to peers like Godrej Industries and Deepak Nitrite, and has underperformed the Sensex with a year-to-date return of -36.01%.
Why is Yasons Chemex falling/rising?
As of 13-Nov, Yasons Chemex Care Ltd's stock price is Rs 12.20, down 6.15%, with significant underperformance compared to the Sensex. The stock is trading below all moving averages, has seen a 37.5% drop in delivery volume, and is close to its 52-week low, indicating a bearish trend and weak investor sentiment.
Is Yasons Chemex overvalued or undervalued?
As of October 13, 2025, Yasons Chemex is considered overvalued with a PE ratio of 15.59 and an EV to EBITDA ratio of 27.77, despite a recent stock price increase, as it has underperformed by 32.64% year-to-date compared to the Sensex's 6.69% gain.
Why is Yasons Chemex falling/rising?
As of 13-Oct, Yasons Chemex Care Ltd's stock price is at 13.00, up 1.17% today, but down 32.64% year-to-date and 40.91% over the past year. Despite outperforming its sector recently, the stock shows declining investor interest and significant long-term challenges.
How has been the historical performance of Yasons Chemex?
Yasons Chemex has experienced significant revenue growth, with net sales increasing from 36.77 Cr in Mar'22 to 76.53 Cr in Mar'25. However, profitability has declined, with profit after tax falling from 3.43 Cr in Mar'23 to 1.62 Cr in Mar'25, and cash flow from operations remaining negative.
Is Yasons Chemex overvalued or undervalued?
As of October 1, 2025, Yasons Chemex is fairly valued with a PE ratio of 14.39, a price-to-book value of 0.57, and an EV to EBITDA ratio of 26.23, despite a year-to-date decline of 37.82%, indicating growth potential relative to its earnings.
Is Yasons Chemex overvalued or undervalued?
As of October 1, 2025, Yasons Chemex is fairly valued with a PE Ratio of 14.39, significantly lower than its peers, despite a 48.16% decline in stock performance over the past year.
Is Yasons Chemex overvalued or undervalued?
As of September 29, 2025, Yasons Chemex is considered overvalued with a PE ratio of 14.99, an EV to EBITDA of 27.00, and a PEG ratio of 0.52, despite being more attractive than peers like Solar Industries and Gujarat Fluoroch, while also experiencing a year-to-date stock decline of -35.23% compared to a 4.19% increase in the Sensex.
Why is Yasons Chemex falling/rising?
As of 24-Sep, Yasons Chemex Care Ltd is priced at 12.25 with no change, reflecting a significant year-to-date decline of 36.53% compared to the Sensex's increase of 5.97%. The stock is underperforming with decreasing investor interest and is trading below key moving averages, indicating a bearish trend.
Is Yasons Chemex overvalued or undervalued?
As of September 23, 2025, Yasons Chemex is fairly valued with a PE ratio of 14.63, a Price to Book Value of 0.60, and an EV to EBITDA of 24.29, significantly lower than peers like Solar Industries and Godrej Industries, despite underperforming the Sensex with a year-to-date return of -36.53%.
Why is Yasons Chemex falling/rising?
As of 23-Sep, Yasons Chemex Care Ltd's stock price is Rs 12.25, up 0.41%, but it remains below moving averages, indicating a bearish trend. Despite a significant increase in delivery volume, the stock has underperformed with a year-to-date decline of 36.53%, suggesting ongoing challenges in regaining investor confidence.
Why is Yasons Chemex falling/rising?
As of 22-Sep, Yasons Chemex Care Ltd's stock price is Rs 12.20, down 3.17%, with a year-to-date decline of 36.79% and a significant drop in delivery volume. The stock is underperforming compared to the Sensex, indicating challenges in attracting investor confidence.
Why is Yasons Chemex falling/rising?
As of 19-Sep, Yasons Chemex Care Ltd's stock price is at 12.60, down 1.95% today and significantly lower by 34.72% year-to-date. The stock has underperformed its sector and shows declining investor interest, with no immediate catalysts for recovery.
Is Yasons Chemex overvalued or undervalued?
As of September 17, 2025, Yasons Chemex is considered undervalued with a valuation grade upgrade to attractive, supported by a PE ratio of 15.35, a price to book value of 0.63, and a favorable PEG ratio of 0.53, despite a year-to-date return of -33.68%.
Why is Yasons Chemex falling/rising?
As of 17-Sep, Yasons Chemex Care Ltd's stock price is at 12.80, unchanged, and has underperformed its sector by 0.99%. Despite recent short-term gains, the stock has significantly declined year-to-date by 33.68%, contrasting with the Sensex's gain of 7.13%.
Is Yasons Chemex overvalued or undervalued?
As of September 16, 2025, Yasons Chemex is fairly valued with a PE ratio of 15.35, but has underperformed significantly with a year-to-date return of -33.68%, raising concerns about its future growth despite a lower PE compared to peers like Solar Industries and Godrej Industries.
Why is Yasons Chemex falling/rising?
As of 16-Sep, Yasons Chemex Care Ltd's stock price is at 12.80, down 0.39%, and has underperformed its sector today. Despite a positive return over the past week and month, it has declined 33.68% year-to-date, with a significant drop in delivery volume indicating reduced investor interest.
Is Yasons Chemex overvalued or undervalued?
As of September 15, 2025, Yasons Chemex is considered undervalued with an attractive valuation grade, supported by a PE ratio of 15.41, significantly lower than peers like Solar Industries and Godrej Industries, indicating a compelling investment opportunity despite recent underperformance.
Why is Yasons Chemex falling/rising?
As of 11-Sep, Yasons Chemex Care Ltd's stock price is at 12.70, up 1.2% today, but down 34.20% year-to-date and 46.30% over the past year, indicating ongoing challenges despite some short-term positive indicators. The stock has mixed momentum, trading above some moving averages but below others, and has seen a decline in investor participation.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}

